Black Diamond Therapeutics (BDTX) EBITDA Margin (2025)
Black Diamond Therapeutics' (BDTX) quarterly EBITDA Margin came in at 77.9% in Q1 2025.
Powered by 
Analysis
Black Diamond Therapeutics (BDTX) EBITDA Margin (2025) Analysis & Trends
Black Diamond Therapeutics (BDTX) has reported EBITDA Margin for 1 consecutive years, with 77.9% the latest figure, recorded in Q1 2025.
- For the quarter ending Q1 2025, EBITDA Margin changed N/A year-over-year to 77.9%; the trailing twelve-month figure through Dec 2025 stood at 17.89% (changed N/A YoY), and the FY2025 full-year result was 17.89%, changed N/A from the prior year.
- EBITDA Margin held at 77.9% in Q1 2025 per BDTX's latest filing.
- Across five years, EBITDA Margin topped out at 77.9% in Q1 2025 and bottomed at 77.9% in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Black Diamond Therapeutics | 111.58 Mn | 1.07 Mn | - | - |